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Abstract

Vaccinating wildlife against bovine tuberculosis (Tb), in countries with wildlife reservoirs of M. bovis, is thought to be the future solution to prevent livestock from getting re-infected. Five newly attenuated strains of mycobacteria have been developed to provide a possibly better vaccine than BCG against M. bovis in brushtail possums in New Zealand. Strain 2 turned out to give a significantly better protectection against experimental infection with M. bovis in three out of nine measurements when being compared to the none-vaccinated control group. Strains 1 and 5 showed two out of nine; strain 3, 4 and BCG showed zero out of nine measurements of protection that were significantly different than the control group. 
The use of a new scoring system for the analysis of histological slides is evaluated. The scoring of both granuloma characteristics in the liver and acid fast organisms (AFOs) in the lung seems most promising for the use in future microscopical examinations of possums with Tb.





In this project we participated in an AgResearch (New Zealand) trial to compare the efficacy of five new strains of attenuated mycobacteria to that of BCG in protecting possums against experimental challenge with Tb. Histological examination of challenged animals was carried out by E.J. Das and N.T.E. Holtslag to compare between treatment groups and assess the use of granuloma characteristics and AFO presence in detecting differences in vaccine efficacy.

Bovine tuberculosis in different parts of the world 
Bovine tuberculosis (Tb), caused by Mycobacterium bovis, is part of a bacterial complex that also includes human tuberculosis (Mycobacterium tuberculosis). M. bovis continues to be a major economic problem in some countries and is still a serious public health risk in many developing countries. Infections with M. tuberculosis are clinically, radiologically and histopathologically indistinguishable from M. bovis, so an accurate estimation of human infections with M. bovis is hard to make (O'Reily, 1995).  Cattle are assumed to be the major hosts of Tb and form the main vector in the spread to humans. Humans can get infected by consuming unpasteurized milk and by close contact with infected animals and carcasses. 
Eradication of Tb is possible using programs based on the regular testing of cattle and farmed deer herds followed by slaughter of the positive reactors. The screening test used is the traditional intra-dermal tuberculin test. The intra-dermal tuberculin test (either in the caudal skin-fold or a skin-fold in the mid-neck) measures the Delayed Type Hypersensitivity (DTH) reaction to the injected tuberculin, a purified protein derivative from M. bovis (bovine PPD). The site of injection is examined after 72h for any swelling or increased skin thickness caused by the DTH reaction due to a cell mediated immune response. The intra-dermal tuberculin test has a sensitivity of 70-75% and has proved to be reliable as a screening method in cattle (Cousins, 2001). A cervical intra-dermal test, in which a mixture of bovine PPD and avian PPD (from M. avium) is combined, is used as a screening method for farmed deer (Wedlock, 2002).
Tb still persists in a lot of countries in which such an eradication program is not politico-culturally accepted and/or unaffordable, mainly in developing countries (Wedlock, 2002; Buddle, 2002-2006). Attempts to eradicate Tb from cattle and farmed deer by using the test and slaughter method has in some countries failed to succeed because of the presence of M. bovis in wildlife reservoirs, because when a wildlife reservoir exists livestock can continually become re-infected. In the case of a wildlife reservoir the only option for eradication of the disease is to control M. bovis in both the wildlife and domesticated populations (Aldwell 2003; Buddle, 2002-2006).   
Wild animal populations infected with Tb can act as a reservoir not only to domesticated animals, but also to other wild animal species and humans. Relevant wildlife reservoirs are the Eurasian badger in the United Kingdom and the Republic of Ireland (Cheeseman, 1989; O’Reilly, 1995), the bison in Canada (Tessaro, 1990), the cervids and white-tailed deer in the USA (Schmitt, 1997), the African buffalo in South Africa (de Vos, 2001), the wild boar and red deer in Spain (Vicente, 2007) and the Australian brushtail possum in New Zealand (Morris, 1995).  

Bovine tuberculosis in livestock in New Zealand
Bovine tuberculosis is thought to have been introduced to New Zealand together with the introduction of livestock by settlers during the European Colonisation around 1830-1840 (Francis, 1947).
Tuberculosis in livestock has only been recognised as a problem in New Zealand since 1940. Tb in dairy herds resulted in a lower milk production and was the major cause for the occurrence of Tb in humans due to the ingestion of unpasteurized milk (Jamieson, 1960)

Attempts to eradicate Tb in livestock
To screen the incidence of tuberculosis in dairy cattle herds a diagnostic intradermal tuberculin test was voluntarily applied by farmers since 1945 and became compulsory in 1956 (cattle herds that produced milk supply for towns), and in 1961 (all dairy cattle herds) (O'Neil, 1995).
A national Tb eradication program based on all cattle herd testing and slaughtering of positive cows was started voluntarily in 1968 and became compulsory in 1970 because of minimum animal health standards applied in export markets. The eradication program did not succeed in all areas, and an epidemiological investigation in 1971 found an association between herds that became re-infected ('problem herds') and the presence of Tb infected possums (Stockdale, 1976).

Vaccination of cattle
Vaccination of cattle could be a good choice for developing countries in preventing cattle from getting Tb and thus reducing the public health risk. But in countries like the UK, Ireland and NZ there is a lot of export of dairy and beef products and because of international health standards a vaccine for cattle would have to induce protection without causing animals to react in the tuberculin skin test when they have been exposed to M. bovis. The vaccination itself should not interfere with the tuberculin skin test, unless a new test is developed that can distinguish between infected and vaccinated animals. The vaccine should not cause any public health risks, and it would be best if the vaccine would cause hardly any skin reaction in the cattle (Buddle 2002-2006). Developing a vaccine with all these characteristics is a very difficult process. Because an effective vaccine for wildlife in combination with the use of regular test and slaughter of livestock would also solve the problem in countries that have a wildlife reservoir, this could prove to be an important and maybe even easier alternative approach.  

Tb vectors in NZ
Wild animals in New Zealand that have been found positive for M. bovis are: possums, deer, ferrets, pigs, stoats, feral goats, feral cats, hares and hedgehogs. Not all species are significantly relevant as wildlife reservoirs. To determine the relevance of these species one could classify a species as being a ‘reservoir host’ (or ‘maintenance host’), or simply a ‘spill-over host’ (usually scavengers and predators that have a lot of close contact with the reservoir host). Reservoir hosts play a central role in spreading the disease, meaning that control of the disease needs to focus on the reservoir hosts, if you want the incidence of the disease to drop. Whether spill-over hosts are also important in the epidemiology of the disease, and therefore require special attention, depends on whether they act as dead-end-hosts or hosts which can infect domesticated and wild animals (Morris, 1995).
So despite the fact that a lot of wild animals other than possums have been found positive for Tb, these species are relatively unimportant spill-over hosts not involved in the transmission of Tb to livestock (Morris, 1995; Lugton, 1978-97). 

Possums are generally considered the main wildlife reservoir host for Tb in New Zealand, and have been shown to act as the main vector in spreading Tb to livestock (Morris, 1995).  
Characteristics of possum ecology and behaviour allow them to act as vectors in the transmission of Tb infections in livestock: high possum density on forest/pasture boundary areas; the strong preference of possums to eat grass at pasture (Coleman, 2000a); the high prevalence of Tb in possums living within 500m of a forest/pasture boundary (Hickling, 1991a); possums (and ferrets) that are in terminal stages of Tb appear to be oblivious to their surroundings and have been seen wandering on pasture even during the day; the inquisitive behaviour (like sniffing, licking and mouthing) of domestic cattle and deer towards terminally ill possums (and ferrets) (Patterson, 1995; Sauter, 1995).
Ferrets can also act as vectors for Tb infection to livestock, but are believed to get infected through the scavenging of infected possum carcasses, and do not seem to infect each other. This makes it unlikely that they act as a wildlife reservoir host in the absence of infected possums, indicating that eradication of Tb in possums would also eradicate Tb in ferrets (Livingston, 2004).  
Wild deer populations are also infected with Tb (most likely mainly due to infection from possums (Nugent, 1998)), and deer are also known to interact with livestock. However, it is still unclear how important deer are as a vector of Tb transmission to livestock (Coleman, 2000b).

Bovine Tuberculosis in possums
The Australian brushtail possum (Trichosurus vulpecula) was introduced to New Zealand. brushtail possums are opportunistic arboreal folivores that weigh 2-3kg, they are nocturnal and sleep in a den during the day, living a predominantly solitary existence. The reason for introduction of possums to New Zealand between 1837 and 1922 was to establish a fur industry. After approximately 160 years possums have now colonised over 90% of the country, with a total estimated population of 30 million (Hickling, 1991a). M. bovis was first recorded in free-ranging possums in 1967 (Ekdahl, 1970), but in hindsight it is more likely that the first infection in possum populations occurred between 1955 and 1960 (Morris, 1995). Possums are highly susceptible to M. bovis as indicated by pathological lesions found in either naturally infected possums (Jackson, 1995a), or experimentally inoculated possums (Denis, 2005). M. bovis is now endemic in possum populations in 39% (over 10 million ha.) of New Zealand (Ryan, 2006; Livingstone, 2006), with estimated point prevalence in infected possum populations of between 1 and 10% (5% average) (Coleman, 2000a).

Transmission
Transmission of M. bovis between wild possums can be pseudo-horizontal (from mother to young through infectious milk, close contact and grooming), horizontal (between adult possums during close contact when mating, fighting, mutual grooming and den sharing), or indirectly (by environmental contamination of den sites, marking sites and foraging area) (Morris, 1995). 




Tb infections in possums caused by experimental inoculation of M. bovis result in a rapidly progressive fatal disease and they often die between 25-100 days (Corner, 1980-1981; Buddle, 1994). Possums infected by natural exposure seem to survive for much longer periods before they become clinically ill. Naturally infected possums go through a phase of sub clinical infection that results in clinical disease after reduced immunity due to stress (bad weather, food competition, fighting or other diseases). The clinical phase can take about 4.7 months (Ramsey, 2003), but can last up to 3 years (Lugton 1997). During this clinical phase behaviour and growth do not seem to be affected (Jackson, 1995a). If animals become terminally ill, they become less active, body condition declines and weight loss occurs (Morris, 1995; Jackson, 1995a). Terminally ill possums soon die because of organ failure or due to the toxins that are released from necrotic tissues (Jackson, 1995a; Cooke, 1995). 
Tuberculous lesions found during necropsies of experimentally infected possums differ from those found in naturally infected possums. Experimentally infected possums quickly show clinical signs as symptoms similar to wild possums in their terminal stage of infection. This is most likely due to the higher infection dose used in experimental trials, in combination with a possibly more virulent bacterial strain being used, different routes of infection, and the stress of being kept in cages (Jackson, 1995a).
Clinically Tb infected wild possums often have macroscopic lesions in the lungs (85%), the deep and superficial axillary lymph nodes (85%) and the inguinal lymph nodes (68%). Macro- and microscopic signs of generalised infection through haematogenous spread are often found in the liver and less commonly in the spleen, kidney, adrenal glands and bone marrow. In the study of Jackson (1995a), of the possums that had macroscopic lesions at necropsy, 86% showed lesions in at least one of these organs, indicating that haematogenous spread is common and happens relatively early in infection. Macroscopic lesions in the lung ranged from 1 to 60mm in diameter. Discrete nodular lesions were most commonly found, but a lot of small lesions (1-3mm) were found in 24% of the possums with macroscopic lesions. Large irregular grey consolidated areas (>30mm) were found in 15% of the clinically infected possums, but even up to 45% in the terminally ill possums. And all terminally ill possums had lost 50% of their lung tissue due to consolidation (Cooke, 1995).
Infection in the superficial and deep lymph nodes (both axillaris and inguinalis) can cause lesions with a diameter of up to 60mm, containing a caseous substance (necrosis, immune cells and mycobacteria) (Cooke, 1995). Infected lymph nodes have been shown to develop discharging sinuses that intermittently leak caseous contents to the exterior (38% of the cases described by Hickling, and 45% of the cases described by Cook (Hickling, 1991b; Cooke, 1995; Lugton, 1997).
The oral tract is thought to become infected by the natural process of swallowing mucus from the respiratory tract and/or by ingesting caseous contents from discharging sinuses during grooming, as demonstrated by Jackson and Cooke (1995), where almost all naturally infected possums (20 out of 21) had both a discharging sinus and infected mesenteric lymph centres. In addition, 41 out of 43 possums that had clinical lung infections also had infected mesenteric lymph centres (Jackson and Cooke 1995).
The liver was found to be infected at necropsy in 41 out of 73 naturally infected possums. Liver lesions were described often as being small (1-2 mm diameter) and randomly distributed; the largest lesion was 11 mm. Macroscopic lesions found in the spleen during necropsy occurred in 15 out of 73 cases (Jackson and Cooke 1995).

Histological examination of 84 possums that were naturally infected with M. bovis, by Cooke (1995), again showed that Tb in possums is a generalised disease. Infection causes a rapid spread of small histological lesions in multiple organs and tissues, indicative of a poor host response to infection; all the animals that only seemed to have one lesion macroscopically turned out to have multiple microscopic lesions as well (Cooke, 1995).
Small microscopic lesions in naturally infected possums have been described as being aggregations of a few large macrophages with angulated cytoplasmic boundaries (angulated macrophages), and lesser numbers of lymphocytes (Cooke, 1995). In histological slides stained with Ziehl-Neelsen (ZN) the lesions are paler than the surrounding tissue, but Acid Fast Organisms (AFOs) are not always present in or near the lesions (particularly in the liver). Neutrophils infiltrate the larger lesions and the even more expansive lesions also show variable-sized foci of cells with pyknotic nuclei, usually accompanied by caseous necrosis. Affected tissues often show multiple similar sized lesions composed of the same kind of cells, but larger lesions are also found to be surrounded by smaller lesions. The microscopic lesions do not show the typical encapsulation that can often be found in other animals infected with Tb. Only rarely is a poor fibroplasia observed, and this occurs mainly when a whole lymph node is affected. Lesions appear to be more discrete in the liver (and to a lesser extend in the kidneys and adrenal glands), due to the compression of the surrounding tissue (Cooke, 1995). AFOs are mainly located intracellularly within marcophages (with a maximal amount of about 40 AFOs in one section), but some are also present in neutrophils; extracellular AFOs can be found in necrotic tissue. Larger amounts of intra- and extracellular AFOs are often found near larger lesions, but the density of AFOs within the different lesions in an individual possum is relatively the same. However, AFO densities between different individuals is highly variable, not seemingly related to the number or size of their lesions. 
Microscopic lesions in the lungs vary between small clumps of macrophages in alveolar spaces, larger lesions involving more parenchyma (and often blood vessel walls and sometimes bronchioles) and containing more AFO infiltrated macrophages and neutrophils with epithelial desquamation and necrosis. If the lungs are more severely affected, lesions can cause large areas of the lungs to become consolidated. Microscopic lesions in the liver are commonly found and are randomly distributed though out the parenchyma, although only a few involve blood vessel walls. In the spleen, the relatively small microscopic lesions are located around the periphery of periarteriolar lymphoid sheaths and the larger lesions are located between the perivascular lymphoid cells. Very small amount of AFOs can be found in the spleen (Cooke, 1995).
In the study of Cooke (1999), 35 possums were experimentally infected with M. bovis using a solution containing 20-100 CFU, applied in the trachea and flushed towards the bronchi. Histological examination of a subset euthanised at two weeks post challenge showed microscopic lesions in the lungs (5 out of 8) and cranial mediastinal lymph nodes (2 out of 4). At three weeks post challenge, lesions were found in the lungs (7 out of 8), mediastinal lymph nodes (8 out of 8) and in the liver and hepatic lymph nodes (1 out of 8). At four weeks post challenge, lesions were found in the lungs (10 out of 10), cranial mediastinal lymph nodes (10 out of 10), liver (7 out of 10), spleen (6 out of 10) and the bone marrow,  left kidney, left adrenal gland (2 out of 10) (Cooke, 1999). 
Microscopic lesions of the lungs three weeks post challenge were described as perivasculair lesions (uncommon in naturally infected possums) in which the affected vessels were cuffed with macrophages surrounded by a mantle of lymphocytes. Neutrophils were numerous in relatively larger lesions and there seemed to be more Acid Fast Organisms (AFOs) present. At four weeks post challenge the lesions were almost all composed of perivasculair cuffs in association with dilatated lymphatics (uncommon in naturally infected possums) containing macrophages, and lymphocytes were present in the surrounding alveolar septa. Expansive lesions also showed necrosis and/or caseation, and the presence of AFOs increased 10-fold (Cooke, 1999)
In experimentally infected possums the liver can show lesions of up to 11m, but more often small lesions are found randomly distributed thought out the parenchyma, described as cream noduli of only 1-2mm in diameter. Microscopic lesions in the liver are described as randomly distributed small granulomatous foci composed of macrophages and sometimes neutrophils (Cooke, 1999).
In the spleen, lesions of up to 15mm are found, but they are often much smaller. Histological lesions in the spleen are described as granulomatous areas located peripherally around periarteriolar lymphoid sheaths (PALS), and larger lesions involve the lymphoid follicles of PALS (Cooke, 1999)

Immunological response mechanisms to mycobacteria 
Immunity to mycobacteria is characterised by a reaction of the cellular immune system. CD4+ T lymphocytes (T-helper1 cells) seem to be most important in producing an effective immune response to mycobacteria by activating macrophages. Infected macrophages present the mycobacterial antigens on class II Major Histocompatibility Complex (MHC-II), and produce cytokines/chemokines (IL-12, IL-18, TNFα (Wedlock, 1999). Lymphocytes are attracted by the infected macrophages and form a zone surrounding the macrophages called a granuloma (Wedlock, 2002). 
Pre-sensitised mycobacterial specific CD4+ T cells recognise the antigens presented by the MHC-II of the macrophage and become activated by IL-12 and develop by stimulation with IL-12 and IL-18. Activated CD4+ T cells are the major producers of IFN-γ, which is crucial in the activation the macrophages (Flesh, 1995). 
Pre-sensitised mycobacterial specific CD8+ T lymphocytes (T-helper2 cells) are MHC-I restricted and respond to live mycobacteria and soluble antigens (Liebana, 1999). CD8+ T cells also stimulate macrophages by producing IFN-γ, and control mycobacterial reproduction by a granulysin pathway. They kill infected macrophages in order to release mycobacteria (Liebana, 2000) so they can be ingested and killed by dendritic cells (which are more proficient in presenting antigens) or activated macrophages (that can kill the mycobacteria). CD8+ T cells also stimulate B cells to produce an antibody response (Wedlock, 2002; Buddle, 2002).
Activated macrophages can kill the phagocytised mycobacteria by lowering the pH in their cytoplasm and exposing the mycobacteria to reactive oxygen and nitrogen products. (Wedlock, 2002)
Possums that were experimentally exposed to M. bovis in an aerosol chamber (10-20 viable organisms per possum) showed macrophage activation in the lungs at 3 weeks post-infection. Activated alveolar macrophages produced more reactive oxygen, significant levels of nitric oxide (NO), as well as TNF-α. 
A NO-dependent system seemed to have a depressing effect on the reproduction of mycobacteria in the first 3 weeks, but at 4-5 weeks post-infection the NO-generating ability became lost and the mycobacteria started to reproduce massively and macroscopical lung lesions became evident (with some lesions occurring in the liver and spleen). The failure of the macrophages to prevent the mycobacteria from reproducing has probably to do with breakdown of the resistance that macrophages show towards the mycobacteria. Mycobacteria and their components have been shown to actively suppress macrophage activation and/or depress the ability of macrophages to respond to activating molecules such as IFN-γ produced by T cells (Sibley 1988; Hussain, 1999; Denis, 2005). The importance of a T-helper1 IFN-γ response has been shown in a vaccine trail in cattle, vaccines that produced a strong IFN-γ response (due to T-helper1 cells) were more protective then vaccines that produced a strong antibody response (due to T-helper2 cells) (Wedlock, 2000). 
TNF-α produced by activated macrophages contributes to the bactericidal action and influences the organisation of granulomas (Roach, 1999). Persistent TNF-α production results in continuous recruitment of macrophages in granulomas and can be a protective immune response but also leads to further tissue damage by the inflammatory cells and thus a reduced organ function (Wedlock, 2002).

Disease control in the possum populations
Possum population control by culling
Models and the review of historical information have shown that if population densities are reduced it can have a major impact on the prevalence of disease. If possum populations are reduced and maintained below a certain threshold to prevent transmission of M. bovis it is possible to eradicate the infection (Coleman, 2000b; Livingstone, 2001). 
Possum control needs to be socially and politically accepted, with the use of techniques that are cost-efficient, target specific, ecologically safe, humane and sustainable (Atkinson, 1994). An extensive programme of possum control (by large-scale culling with different poisons) especially in Vector Risk Areas (VRAs) has been started in 1994. A VRA is defined by an area in which wild animals have been found, or are suspected, to act as Tb vectors for livestock. The possum control program is part of the New Zealand National Bovine Tuberculosis Pest Management Strategy that has been a major factor in the 86% reduction of Tb infections in cattle herds in 2005 since the start of the possum control program. The progress in the reduction of infected herds compared to the extent of possum control is shown in Fig. 1 (Livingstone, 2006).This reduction has given more evidence to the hypothesis that most cattle and farmed deer get infected by contact with infected possums (Buddle 2000 & 2002). However, this strategy has not led to a reduction of the area in which M. bovis is endemic in possum populations, likely due to the migration of infected possums (mostly juveniles). VRAs covered 23.6% of NZ in 1998 (Animal Health Board, 1998), and had extended to 39% by 2005 (Livingstone, 2006). The geographical spread of the VRAs in 2005 is shown in Fig. 2. 




Fig. 1 Number of infected cattle and deer herds at June each year 
relative to the cumulative area (million hectares) of NewZealand 
receiving possum and ferret control during the period June 1991 










Fig. 2 Map of New Zealand showing Vector Risk and 




Fertility control in possums
Fertility control of possums is a tool being developed as a more humane and environmentally acceptable method of population control (Cowan, 2000). Current research is focusing on developing immunocontraception (immunological blocks to prevent fertilisation or embryonic development) (Cowan, 2000), and immunologic interference with central hormonal control of reproduction through the use of gonadotrophin-releasing hormone (GnRH) vaccines or GnRH-toxin conjugates to disrupt pituitary gonadotropes (Herbert, 2005).
A combined approach of vaccination and fertility control may provide a more efficient method in reducing the prevalence of Tb in possum populations than vaccination alone. Infertile animals do not reproduce so there will be no increase in the susceptible population. Sterilised infected animals that do not produce reproductive hormones are less likely to show breeding behaviour or dominance based aggression between competing males which could reduce Tb transmission between possums (Caley, 2001).
In a study with wild possums there was no significant association between gonadectomy of female and male possums and the occurrence of infection with M. bovis, but there was a 53% reduction in the force of infection in gonadectomised males compared to intact males in the same area (Ramsey 2006).

Tb control in possums with the use of a vaccine
The ultimate goal of vaccinating wildlife against Tb is to eradicate the infection from wildlife reservoirs. A relatively easier goal would be preventing Tb transmission between both wild animals, and wildlife and livestock. That would be enough to break the chain of re-infection of livestock by reservoir hosts. Preventing excretion of Tb from infected animals instead of preventing the initial establishment of an infection could be possible with a vaccine that reduces the severity of clinical disease (Buddle, 2002; Skinner 2002; Aldwell, 2003; Buddle, 2006). However, before achieving this, there are still some difficulties to overcome like finding a way to deliver the vaccine to a sufficient majority of the wildlife population to cause a reduction of Tb in livestock. The frequency of re-vaccination also needs to be established, depending on the length of protective immunity, birth rate and possible immigration of animals. Vaccines that require only a single dose, without having to administer a booster, should be used because it would be even more difficult to make sure the vaccinated individuals could be reached twice. Vaccine delivery to the mucosal surface is preferred because of the stimulation of both systemic and mucosal immunisation. Mucosal delivery can be accomplished by using either oral baiting or an aerosol spray to deliver an intranasal/intra-conjunctival vaccine. This makes the use of oral bait that contains a live vaccine (that only needs to be administrated ones) the most promising option (Buddle, 2002-2006; Skinner, 2002).
The traditionally used vaccine against M. tuberculosis in humans and M. bovis in both humans and animals is bacillus Calmette-Guérin (BCG). BCG is a live attenuated vaccine of M. bovis, has been used for over 80 years in both animals and humans, and is a good candidate for the vaccination of wildlife, because it is safe, relatively cheap to produce and easy to deliver. BCG has shown to cause less (and smaller) lung lesions, fewer microscopic lesions in liver and spleen, lower bacterial counts especially in the spleen and reduces the loss of body weight following challenge with M. bovis (Aldwell, 1995; Skinner 2002; Buddle, 2006; Cross, 2007a). 
Although BCG has been used for so long its efficacy in the protection against Tb has been variable in both human and animal trails with success rates between 0 and 90% (Colditz, 1994; Fine, 1998). 
Because of the variable level of the protection achieved by BCG there is a constant search for ways to improve or replace the BCG vaccine for use in both animals and/or humans. The genomes of M. tuberculosis and M. bovis have been sequenced showing them to be very closely related, providing more evidence that a vaccine effective against M. tuberculosis could also be effective against M. bovis, and the other way round (Buddle, 2006).

Vaccine delivery strategies 
The BCG vaccine has been delivered via subcutaneous, intranasal, intra-conjunctival routes and in oral baits in different vaccination trails.  The use of oral baiting has many advantages: easy to administrate, low costs, avoidance of needles and oral immunisation has the potential of generating both a systemic and a mucosal immunity against Tb (Aldwell 2003).This makes oral baiting the ideal vaccine delivery method to use for large scale vaccinations in wild animal populations (World Health Organization 2004; Cross, 2007b). 
BCG was administered to possums either unprotected orally, unprotected intraduodenal or orally 1h after the administration of Ranitidine (a drug that reduces the acidity of the stomach). Unprotected oral BCG showed only very little protection against M. bovis, but both intraduodenal administration and the use of Ranitidine greatly improved the efficacy of BCG (Buddle, 1997; Skinner, 2005). 
Aldwell demonstrated that oral vaccinations in possums induced levels of protection against aerosol challenge of M. bovis that were similar to BCG vaccination by subcutaneous injection. He used different formulations of lipid as a matrix surrounding live BCG in order to protect the mycobacteria against the low pH of the stomach and the work of digestive enzymes (Aldwell, 2003). 
This indicates that the success of an oral BCG vaccine is mainly depending on the ability of a matrix to cover and protect the live BCG mycobacteria against early breakdown, but the matrix should also allow an efficient delivery of the BCG mycobacteria to the gastrointestinal immune induction sites (GALT). 
It has also been demonstrated that a sufficient titre of BCG is needed in the intestine to allow a big enough population of BCG mycobacteria to replicate in the gastrointestinal immune system before a protective systemic immune response can be generated (Aldwell, 2003; Skinner, 2005; Cross, 2007c). 
Guinea pigs and mice models are being used to test many more different formulations of matrix that can be used in oral BCG vaccines. Guinea pigs vaccinated with life BCG in Lipid PK matrix showed a significant protection against aerosol challenge with M. bovis that was indistinguishable from the subcutaneous BCG vaccine. Other promising oral vaccines contain live BCG in a matrix of alginate beads and a novel micro-capsule formulation based on the encapsulation of BCG-lipid in alginate (Clark, 2008). The use of candidate formulations of oral vaccines should also be tested again in possums because the results generated from mice and guinea pig models can only give an indication about their potential effect on the protection conferred against Tb. Guinea pig for example have relatively less gastric lipase activity compared to other species (de Nigris, 1988).
Oral vaccination with live BCG mycobacteria has already been shown to lower lung and spleen infection, leading to a reduction in the pathological changes that occur in the lung and less spread of the infection to extra-pulmonary sites in possums that were experimentally challenged with M. bovis compared to non-vaccinated possums (Aldwell, 2003; Buddle, 2006; Collins, 2007). So, despite the fact that the vaccine did not prevent the initial infection to occur; it did slow down the disease progression in experimentally challenged possums. And because Tb infections in possums due to experimental infection cause a more rapid, harsh and unnatural disease than in naturally infected possums it is likely that an oral vaccine would give a significantly better protection and possibly even prevention of disease in free-ranging possums, as was demonstrated by Tompkins (Tompkins, 2009). In the Orongorongo Valley a study was performed in which live BCG mycobacteria formulated in a protective lipid matrix was used in oral baits to vaccinate free-ranging possums against natural exposure to M. bovis. 1 out of 51 vaccinated possums got infected compared to 12 out of 71 non-vaccinated possums (Tompkins, 2009). More field trails need to be done before large-scale vaccination with the use of oral baits can be performed for real. But oral bait vaccination is expected to deliver promising results in reducing the prevalence of Tb in possum populations (Tompkins, 2009).

Killed-, subunit-, protein- or DNA-vaccine in combination with BCG 
Vaccination with dead BCG results in a poor, if any, level of protection; the efficacy of BCG depends on the survival and persistence of the mycobacteria or its products (Gheorghiu, 1996).
An intranasal vaccine made of a combination of live BCG and heat-killed Mycobacterium vaccae (100 µg) gave a significant better protection against experimental challenge with M. bovis in possums compared to a vaccination with BCG alone (Skinner, 2002). Why M. vaccae has an effect while other killed mycobacteria do not is unclear, but it has been shown that killed M. vaccae contain T-helperl promoting activities that stimulates natural killer cell activity and CD8+T cells that specifically lyses mycobacteria infected macrophages (Skinner, 1997). The administration of the low dose of M. vaccae (100 µg) in combination with BCG gave better results than the high dose (3 mg), possibly because of the stimulation of a T-helper1 response instead of both a T-helper1 and-2 response (Skinner, 1997).
The use of subunit or DNA vaccines alone has the disadvantage that they require multiple vaccinations and they have not been able to provide a higher level of protection than the BCG vaccine (de Lisle, 1999). But there are many vaccination trails in which BCG combined with subunit vaccines (consisting of proteins and peptides) has led to a higher level of protection (wedlock, 2008). Subunit vaccines can contain a combination of adjuvants* and Mycobacterial Protein Vaccine-Adjuvants like culture filtrate proteins (CFPs). 
A study on 6 month old calves demonstrated that calves vaccinated with a combination of BCG, culture filtrate proteins (CFP from M. bovis) and a Toll Like Receptor 2 agonist (TLR2)** had a significantly higher level of protection against intra-tracheal challenge with M. bovis than calves vaccinated with just BCG. The calves vaccinated with the combination showed less macro- and microscopic lung and lymph node lesions (Wedlock, 2008). A similar vaccination trial in mice also suggests a role for TLR2 agonists in the improvement of vaccines against Tb (Wang, 2007).

Different attenuated strains of BCG
In order to develop a more efficacious vaccine against Tb in possums, different strains of M. bovis have been produced; the mutants that proved to be avirulent after subcutaneous injection in guinea pigs were selected and used to test their efficacy in protecting guinea pigs against Tb. One of the strains (WAg533) turned out to give a higher level of protection against aerosol challenge with M. bovis then BCG. Because of the concern that live vaccines might become virulent after a single mutation or in immuno-compromised animals (De Lisle, 1999; Collins, 2002; Hotter, 2005), new live vaccines are only likely to be accepted for large-scale use in animal or human populations if their genetic changes have been defined precisely.







*Adjuvants are immunological agents that modify the effect of vaccines while having few if any direct effects when given by themselves.
** TLRs are a family of gateway receptors which can initiate the activation of the innate immunity, if they recognise an infectious agent.
In 2007 a study was published in which possums were vaccinated with either BCG, or the newly attenuated strain of M. bovis (WAg533) to compare its efficacy against Tb. The possums were vaccinated with WAg533 in comparison with BCG by three different inoculations: intra-conjunctival + 
intranasal, oral baiting or subcutaneous injection. The effects of the different vaccinations were 
measured by a Lymphocyte proliferation assay (LPA), clinical findings, pathology and bacteriology. 
The WAg533 strain turned out to be significantly better at protecting the possums against aerosol challenge with M. bovis than the BCG vaccine, compared to the non-vaccinated group (Collins 2007).


Aims of the study

1.	To compare the efficacy of five new attenuated mycobacterial strains to that of BCG in protecting possums against experimental challenge with Tb.





Date	7th of May	27th of May	24th of June	20th of July	24th of August	10-14th of Sept
Activity	Caught	Vaccinated		Challenged		Necropsied
Specifications	Animals were anaesthetized, bled (for LPA) weighed and palpated for lesions 	Animals were anaesthetized,  vaccinated subcutaneously; weighed and palpated for lesions	Animals were weighed, and palpated for lesions at vaccination site  	Animals were weighed, and palpated for lesions at vaccination site  	Animals were weighed, and palpated for lesions at vaccination site  	Animals were euthanized with CO2 and Necropsied 
Table1: Time-schedule possum trail 

2.1. Bacteria and media
The vaccine strains of M. bovis used were Strain 1, Strain 2, Strain 3, Strain 4, Strain 5 and BCG Pasteur 1173P2. The challenge strain used was M. bovis 83/6235, which was originally isolated from a tuberculous lesion of a possum and has been used in previous vaccination studies on brushtail possums (Adwell, 2003). Liquid culture of all strains was performed in Tween-albumin broth (Kent, 1985) or supplemented Middlebrook 7H9 (Difco) medium (Collins, 2002). For vaccination, organisms were grown to mid-log phase, the number of organisms was estimated from the optical density of the culture, and diluted to the required concentration in sterile phosphate buffered saline (PBS) for subcutaneous inoculation. The number of colony forming units (cfu) in the vaccine suspensions was determined subsequently by plating 10-fold dilutions on modified Middlebrook 7H11 agar supplemented with  albumin/dextrose complex (ADC, Difco), 0.05% Tween 80, and 0.5% glycerol for BCG and Strain 1-5 (Collins, 2007). 

2.2. Animals
Twenty-two female adult and twenty-one male adult brushtail possums (Trichosurus vulpecula) weighing 1.6–3.6 kg were captured from the Manawatu region of New Zealand (Tb free area). The animals were acclimatised to captivity for 3–4 weeks prior to the experiment to decrease the effect of stress caused by capture and housing in cages (Buddle, 1992). During the acclimatisation period blood samples were collected for testing for reactivity to purified protein derivative from M. avium (avian PPD) and M. bovis (bovine PPD) using a lymphocyte proliferation assay (LPA) to confirm the animals had not been previously exposed to M. bovis infection. The animals were examined thoroughly for any clinical diseases and housed individually in wire cages (90×67×40 cm) with a nest box (40×25×25 cm) attached to the exterior of one side of the cage. The animals were maintained on a diet of carrots, apples, pasture weeds and commercial pellets, with water available ad libitum (Buddle, 1994).
The possums were divided into groups based on their sex and body weight with the use of a stratified sampling system to ensure that all groups contained animals of a similar size and female/male ratio. They were then randomly allocated into seven groups (control, BCG vaccinated, Strain1-5 vaccinated). 
The animals were anaesthetised before weighing, bleeding, vaccination, challenge and euthanasia with 0.8m of 100mg/ml Ketamin per kg of bodyweight, as previously described (Buddle, 1994).  At 1-2 week intervals each possum was anaesthetised, weighed, palpated in the areas of the superficial axillary and inguinal lymph nodes and 2 ml of blood collected via the jugular vein before vaccination and at intervals during the course of the vaccination-challenge experiment for lymphocyte proliferation assays. At the end of the experiment, anaesthetised possums were euthanized by administration of CO2. 
The Wallaceville Animal Ethics Committee, Upper Hutt, New Zealand, approved all animal experiments.
2.3. Peripheral blood lymphocyte proliferation assay (LPA)
Lymphocyte proliferative responses to avian and bovine PPD (Pfizer Limited, Parkville, Australia) were measured using whole blood depleted of red blood cells as previously described (Skinner, 2002). The stimulation index (SI) was calculated by dividing counts per minute (cpm) from triplicate cultures stimulated with PPD by cpm from triplicate cultures with medium and PBS.

2.4. Vaccination of brushtail possums
The vaccinations took place on 27th May 2009. The vaccines were all delivered subcutaneously behind the shoulder to prevent the possums from scratching the injection site. Six possums were not vaccinated, and served as the control group. Six other groups of six possums received 5x106 cfu of BCG and Strains 1-5 in 0.5 ml, respectively.

2.5. Aerosol challenge and euthanasia
All possums were challenged on 20th July 2009, 54 days after vaccination, with a low-dose aerosol of M. bovis (10–20 viable organisms per possum) in an aerosol generating chamber as described previously (Adwell, 2003). Animals were euthanized by CO2 inhalation between 10th - 14th September 2009 (21-25 days after being challenged), and subjected to gross post-mortem examination. 

2.6. Necropsy
The lungs were separated from surrounding tissue and weighed.
Pieces of lung, liver and spleen weighing approximately 1 g each were taken from macroscopic lesions for bacterial count and histological examination. When lesions were not present, tissue was collected from the middle of the lobus for the liver, or the middle of the spleen.

2.7. Bacterial count
Lung, liver and spleen samples were cultured for M. bovis on sodium pyruvate supplemented media. Solid culture of M. bovis from possum tissues (1g lung, liver or spleen tissue) was performed on Tween-albumin broth (Kent, 1985) or supplemented Middlebrook 7H9 (Difco) medium (Collins, 2002), with the addition of 0.6 ml/l oleic acid, 2% glucose, 0.77% NaCl, 0.5% lysed sheep red blood cells, 10% bovine serum, 10µg/ml fungizone, 200 IU polymixin B sulphate, 100µg/ml tarcarcillin and 10 µg/ml trimethoprim (Buddle, 1994; Collins 2007)). The minimum detectable level of viable bacteria in lung, liver and spleen homogenates was 10 CFU/organ sample.

2.8. Histology
Tissue samples of the lung, spleen and liver were fixed in formalin for histological examination. The formalin fixed pieces were than embedded in paraffin and cut at 4 µm and stained in two different ways: haematoxyline and eosine (H&E) and Ziehl-Neelsen (ZN) stain (Culling, 1985).
The histological slides were scored by E.J. Das and N.T.E. Holtslag with the use of a scoring system based on microscopic pathological findings described previously in possums after both experimental (Buddle, 1994; Cooke, 1999) and natural (Cooke, 1995) challenge with M. bovis. 
The scoring system was based on the tuberculous granulomas and included the determination of the location, measuring the size and grading the stage of the granulomas found in the lung, liver and spleen. In the lung the presence of Acid-fast Organisms (AFO’s) was also estimated in the histological slides stained with Ziehl-Neelsen.
The histological tissue samples were also examined by T. Wilson, in order to see whether E.J. Das and N.T.E. Holtslag used the right kind of scoring system and whether they performed it adequately. T. Wilson only looked at the liver samples and scored the total amount of granulomas present for each individual; she also scored the granulomas size by categorising them as being small, medium or large. 

2.8.a Histology of the Lung
The histological slides of the lung were almost always taken from the site of a tuberculosis lesion. Hence it was not practical to count all of the granulomas present because there was usually one really big granuloma or many smaller granulomas, which were often not possible to distinguish from one another. Hence, only the granulomas present in the air containing alveolar tissue that showed the ‘normal’ structure and was not consolidated were counted. Both the size and the stage of the recognisable granulomas were scored as described below (2.8d-f).
With the histological slide stained with Ziehl Neelson we checked the amount of Acid-fast organisms (AFOs). The amount of AFO’s we determined by looking through different parts of the lung. Where most AFOs were observed, the number in one field of view at 10x40 magnification was counted. We scored each slide as having ‘none’, ‘few’ (1-10), ‘several (11-25) or ‘lots’ (> 25) of AFOs.

2.8.b Histology of the liver
Granulomas were observed in every part of the liver; location was scored as either ‘near central vein’, ‘near big vein’, or ‘near portal triad’. The locations of the granulomas not described specifically were all ‘surrounded by normal hepatocytes’. Granulomas were scored by size and stage as described below (2.8d-e).

2.8.c Histology of the Spleen
In the spleen granulomas are commonly found around the edge of germinal centres; these locations were examined for the presence of granulomas. Granuloma size and stage was scored as described below (2.8d-e).

2.8.d Scoring the granulomas by size: 
The diameter of all granulomas was measured (Figure 3 shows an example) using with the arrow in the ocular of the microscope,which was also used to measure how many erythrocytes could fit in the total length of an arrow. Eighteen erythrocytes were counted in the full length of 1 arrow at 10x10 magnification. Erythrocytes have a diameter of 7 µm, which makes the length of 1 arrow approximately 125 µm. 
At 40 times magnification the arrow length was adjusted to 625 µm.
All granulomas were scored as single entities, even when potentially formed by the fusion of multiple structures.

 




Figure 4. The same granuloma as Figure 3, the arrow points towards necrosis, indicating a stage 4 granuloma.

2.8.e Scoring the granulomas by stage:
Granulomas contained only macrophages were classified stage 1. Those also containing neutrophil granulocytes we or pyknotic cells were classified stage 2 and 3 respectively. Those with necrosis present were classified stage 4 (Figure 4 shows an example).

2.9 Statistical tests used to analyse the data
The Normal distribution of the data was tested by the Anderson-Darling Normality test and, if necessary, data was log10 transformed prior to analysis. Bacterial counts from the lung and spleen were also log10 transformed prior to analysis and, for statistical purposes, half the lowest detectable count (5 CFU/g tissue) was used when no bacteria were cultured. The body weight changes, lung weights, bacterial counts and histological granuloma and AFO scoring among the different treatment groups were compared by General Linear Model analysis of variance, with the use of Ministat 15. Both treatment, sex and weight at vaccination were included in the statistical models constructed to prevent possible confounding factors from influencing the results. Microsoft Office Excel was used to calculate means and standard deviations for the different treatment groups, and to graph them. The scoring system used by E.J. Das and N.T.E. Holtslag was compared to that of T. Wilson using the Pearson correlation test. 
Results 
Animal condition
All animals turned out to be Tb-free before they were vaccinated and challenged, and they survived until the end of the challenge trial, with none needing to be euthanized on ethical grounds. One of the control animals turned out to be negative in the bacterial counts, therefore this individual is not included in the results. There were no significant differences in body weight between either the two sexes or the treatment groups at either vaccination or challenge (Appendix I: Table 1), with challenge weight being positively correlated to the earlier vaccination weight (F1,34 = 8.49, P = 0.006). However, body weight did differ significantly among treatment groups upon necropsy at the end of the trial (Figure 5; F6,34 = 3.07, P = 0.017), controlling for challenge weight (F1,34 = 208.13, P < 0.005). Necropsy weights for possums in treatment groups two (Dunnett t = 3.56, P = 0.006) and five (Dunnett t = 2.98, P = 0.02) were significantly lower than those for the control animals.

Pathology
To estimate the amount of consolidation in the lung, the % of lung weight of the overall necropsy weight was measured. A higher % indicates a more consolidated lung, caused by tuberculous pneumonia (Collins, 2007). The possums in treatment group one, two and five had lower lung weight % than the control group, although the differences were not significant (Tabel 2, Figure 6, F6,34 = 1.33, P = 0.270).

Vaccine group	% Body weight loss a	% lung weight/ necropsy weight b	Spleen Log10 CFU/g c	Lung Log10 CFU/g c
Strain 1 (N=7)	1.49 ± 3.72	0.94 ± 0.43	1.07 ± 4.14*	5.06 ± 1.52
Strain 2 (N=6)	7.60 ± 5.16*	0.89 ± 0.25	0.95 ± 0.52*	5.18 ± 1.09
Strain 3 (N=7)	-5.27 ± 7.86	1.19 ± 0.50	2.14 ± 1.03	6.08 ± 1.83
Strain 4 (N=6)	-3.52 ± 9.10	1.28 ± 0.75	2.11 ± 1.23	6.09 ± 0.91
Strain 5 (N=7)	5.27 ± 13.59*	0.92 ± 0.46	1.09 ± 1.01*	4.86 ± 2.44
BCG (N=6)	-3.55 ± 5.56	1.38 ± 0.55	1.89 ± 0.84	6.61 ± 1.06
Control (N=5)	-10.96 ± 7.19	1.56 ± 0.29	3.44 ± 1.86	6.95 ± 0.69
Table 2. Animal condition, pathological and microbiological findings for possums vaccinated with 5 different new attenuated mycobacteria strains, BCG and a non-vaccinated control group before challenge with M. bovis.
a % Body weight loss: body weight at challenge (kg) – body weight at necropsy (kg) divided by the body weight at challenge and expressed as a percentage (mean ± standard deviation).
b % lung weight / necropsy weight: lung weight (kg) divided by body weight at necropsy (kg) and expressed as a percentage (mean ± standard deviation).
c Log10 CFU/g: the log10 of number of colony forming units per gram of tissue (mean ± standard deviation). 
* Significant difference compared to the non-vaccinated control group (P = <0.05).


Figure 5. Weight loss between challenge and necropsy, and expressed as a percentage (%) (mean ± std).
Figure 6. Lung weight compared to body weight at necropsy, and expressed as a percentage (%) (mean ± std).

Figure 7. Spleen bacterial counts of the different treatment groups (mean ± std).
Figure 8. Lung bacterial counts of the different treatment groups (mean ± std).

Bacteriology
The mean numbers of M. bovis in the lungs and spleen are shown in Table 2 and Figure 7 and 8. All animals that were vaccinated had lower bacterial counts in both the spleen and the lungs than the control group. Bacterial counts in the spleen differed significantly among treatment groups (Figure 7; F6,34 = 3.07, P = 0.017), but were only significantly lower than the control group for groups one (Dunnett t = -3.39, P =0.009), two (Dunnett t = .3.50, P = 0.007) and five (Dunnett t = -3.30, P = 0.011). Bacterial counts in the lungs were not significantly lower than the control group in any of the treatment groups. 





Vaccine group	Size a	Stage b	Size a	Stage b	Size a	Stage b	AFOc
train 1 (N=7)	121.92 ± 55.48	1.34 ± 0.50	-	2.29 ± 1.16 *	-	68.45 ± 87.23	0.50 ± 0.60*
Strain 2 (N=6)	97.81 ± 21.33	1.13 ± 0.11	-	2.00 ± 0.58 *	-	50.00 ± 111.80	0.50 ± 1.12*
Strain 3 (N=7)	149.64 ± 69.79	1.20 ± 0.27	129.90 ± 206.80	3.29 ± 1.16	0.43 ± 0.73	136.77 ± 255.25	0.63 ± 1.18
Strain 4 (N=6)	107.24 ± 46.41	1.24 ± 0.21	62.50 ± 139.80	3.00 ± 0.82	0.33 ± 0.82	67.36 ± 112.02	0.47 ± 0.71
Strain 5 (N=7)	115.14 ± 42.53	1.28 ± 0.30	62.50 ± 139.80	2.83 ± 1.21	0.17 ± 0.37	130.56 ± 133.98	0.78 ± 0.96
BCG (N=6)	103.92 ± 56.94	1.20 ± 0.45	-	2.83 ± 0.69	-	336.18 ± 287.62	2.26 ± 1.49
Control (N=5)	172.00 ± 41.88	1.54 ± 0.49	75.00 ± 150.00	4.00 ± 0.00	0.56 ± 1.12	-	-

Table 3. Characteristics of the granulomas scored in the histological coupes of different tissue samples, stained with H&E.
a Size: the measured diameters of the granulomas we scored (µm) (m ± std).
b Stage: the stages of the granuomas we scored (1 = macrophages present; 2 = neutrophils present; 3 = cells with a picnotic nucleolus present; 4 = necrosis present) (m ± std).
c  Lung AFO: The number of AFOs scored in the lung (1 = none AFOs; 2 = few = 1-10 AFOs; 3 = several = 11-25 AFOs; 4 = lots = >25 AFOs) (m ± std).
- No granulomas were scored.




The lesions in the liver looked quite different depending on their size and stage (Appendix II, Table 1-3). Lesions were generally either (i) small (50-75µm), containing a lot of macrophages and a variable amount of affected hepatocytes and lymphocytes (Figure 9); (ii) medium (75-150µm), often containing large amounts of macrophages and one or several neutrophils, and a variable amount of lymphocytes; (iii) large (150-300µm), often containing large amounts of macrophages, sometimes neutrophils, variable amounts of lymphocytes and at least one cell with a picnotic nucleolus; (iv) huge (>300 µm), often containing macrophages, lymphocytes, sometimes neutrophils and/or picnotic nucleoli and centrally located necrosis. These sizes and stage characteristics were not always this strictly correlated (Figure 10). 
Lesions in the spleen often looked quite similar. They were usually located on the edge germinal centers and were recognisable by the looks of the cells involved. The cells containing the granuloma were often elongated and pale compared to other cells found in the spleen (Figure 11-12). Differentiation between a tuberculous granuloma and an exhausted germinal center could be made on the looks of the cells involved, and the location in the granuloma. An exhausted germinal center distinguished itself by being located near the centre of a germinal center, containing pale cells that were often still more or less round; sometimes neutrophils, cells with a picnotic nucleolus and, or necrosis was present in the granulomas. 




Figure 9. One relatively small granuloma	     	        Figure 10. One relatively medium to large 
 in the liver, containing mostly macrophages 	        granuloma in the liver, containing mostly
and lymphocytes (photo was made with a 40 	        macrophages and a few neutrophils (photo was
times magnification).				        made with a 20 times magnification).

							  Figure 11. Five granulomas present
































Figure 13-14. One relatively large granuloma in the 
lung containing mostly macrophages and lymphocytes,
but also shows a couple of cells with a picnotic nucleolus 
(the left photo was made with a 20 times magnification, the right photo with a 40 times magnification).

Granuloma characteristics from the liver (Figure 15-18), spleen and lungs are shown in Table 3. All granuloma characteristics were not normally distributed, and therefore were log10 transformed prior to analysis. There was no significant difference in the total number of granulomas scored among treatment groups, however groups one (Dunnett t = -2.11, P = 0.163) and three (Dunnett t = -2.12, P = 0.160) tended to be lower than the control group. There was also no significant difference in the size of the scored granulomas in the liver among treatment groups, however groups two (Dunnett t = -2.08, P = 0.173) and BCG (Dunnett t = -2.24, P = 0.128) tended to be smaller than the control group. Likewise, there was no significant difference in the size index of the scored granulomas in the liver among treatment groups, however groups two (Dunnett t = -1.85, P = 0.266)  and BCG (Dunnett t = -2.30, P = 0.114) again tended to be smaller than the control group. There were also no significant differences in the stage of the scored granulomas in the liver among treatment groups. The granuloma characteristics of both the lung and the spleen are not included in further analyses due to a large number of zero counts.





Figure 15-18. Characteristics of the liver (log10 transformed): Total number of granuloma (Tno granuloma), granuloma size index, actual granuloma size and granuloma stage (mean ± std).






Figure 20. The median AFO score for strains 1 and 2 was 2 which stands for few (= 1-10 AFOs), the median for strains 4, 5 and 6 (=BCG) was 3 which stands for several (= 11-25 AFOs), and the animal group vaccinated with strain 3 and control group both had a median of 4 which stands for lots (>25 AFOs). 
Results of correlations between the bacteriological counts and the microscopic examinations
Several of the liver microscopic characteristics scored were correlated with each other, and with the lung AFO score and the spleen and lung bacterial counts. 
The liver granuloma size index was significantly correlated to the actual liver granuloma sizes recorded (Figure 21, Pearson correlation = 0.69, P = <0.005), and the actual liver granuloma sizes and stages were correlated with each other (Figure 22, Pearson correlation = 0.57, P = <0.005).
In addition, the granuloma stages observed in the liver correlated with those in the spleen (Figure 23, Pearson correlation = 0.93 , P = 0.021), and the size and stage of the granulomas found in the lung were correlated (Figure 24, Pearson correlation = 0.69, P = 0.003). 
The total number of granulomas scored in the liver was significantly correlated to Lung AFO score (Figure 25, Pearson correlation = 0.37 , P = 0.016), lung bacterial count (Figure 26, Pearson correlation = 0.58, P = <0.005) and spleen bacterial count (Figure 27, Pearson correlation = 0.51, P = 0.001). The granuloma sizes scored in the liver were only significantly correlated with the spleen bacterial count (Figure 28, Pearson correlation = 0.41, P = 0.006); neither the granuloma size index or granuloma stages scored in the liver were significantly correlated with either the Lung AFO score or the bacterial counts. The Lung AFO score was significantly correlated with the bacterial counts of both the lung (Figure 29, Pearson correlation = 0.73, P = <0.005) and the spleen (Figure 30, Pearson correlation = 0.64, P = <0.005).
There was also a significant correlation across all experimental groups between spleen and lung bacterial counts (Figure 31, Pearson correlation = 0.64, P = <0.005), although the relationship was non-linear with lung counts increasing more rapidly than spleen counts.


Figure 21. Liver granuloma size index correlated with the actual size measured, both Log10 transformed.
Figure 22. Liver actual granuloma size correlated with stage, both Log10 transformed.


Fig 23. Liver granuloma stage correlated with spleen stage, both Log10 transformed.
Fig 24. Lung actual granuloma size correlated with lung, both Log10 transformed.


Figure 25. Liver Tno of granulomas (log10 transformed) correlated with lung AFO score.
Figure 26. Liver Tno  of granulomas correlated with lung bacterial counts (CFU/g), both log10 transformed.

Figure 27. Liver Tno of granulomas correlated with spleen bacterial counts (CFU/g), both log10 transformed.
Figure 28. Liver actual granuloma size correlated with spleen bacterial counts (CFU/g), both log10 transformed.

Figure 29. Lung bacterial counts (log10 CFU/g) correlated with lung AFO score.
Figure 30. Spleen bacterial counts (log10 CFU/g) correlated with lung AFO score.
 




Subcutaneous vaccination of brushtail possums with BCG shows only a small non-significant reduction of disease after aerosol challenge with M. bovis on comparison to a non-vaccinated control group. Here, different measurements were used to qualify the severity of infection during clinical, pathological, microbiological and microscopic examinations of vaccinated possums. The efficacy of five new attenuated mycobacterial strains in preventing disease on upon challenge with Tb were compared with the control animals, with strains 1, 2 and 5 demonstrating significant reductions in disease.

This study demonstrates that a few newly attenuated mycobacterial strains are more potent vaccines than BCG in the protection of possums against aerosol challenge with virulent M. bovis. Strains one and five both had two out of the nine measurements of protection examined that were significantly better than the non-vaccinated control group. Strain 2 had three out of nine measurements of protection that were significantly better than the control group. Strains 3 and 4, as well as the BCG vaccine, all had no measurements of protection that are significantly better than the control group. When the strains were directly compared to BCG none of the new attenuated strains were significantly better, and only Strain 2 tended to be different from BCG in percentage of body weight loss between challenge and necropsy (Dunnett t = 2.24, P = 0.134). 

Different methods of administration for live vaccines are still being studied, but in the current study the traditional subcutaneous injection method was used to compare the different live vaccines. The advantage of the SC vaccine administration is that there are less variables that might influence the delivered doses of the vaccine. In the case of a live vaccine, SC injection has little influence on the viability of the organisms compared to the use of oral baiting, which makes SC injection a better method for obtaining the reproducible results needed in research trials (personal comment B.M. Buddle). So although oral baiting is most likely to be used in wild possum population, there is still not enough experience with the use of oral baiting for it to be used in all research trails. 

In this study the animals were challenged with a low-dose aerosol of M. bovis (10–20 viable organisms per possum) in an aerosol generating chamber. Intra-tracheal challenge is currently the challenge method mostly used in captive possums, although intra-conjunctival challenging (a doses of 1000-2000 cfu in a 50 μl suspension) seems to have more practical advantages (easier, non-invasive procedure which only requires sedation) and is more similar to the natural infection because of the slower disease progression. Possums challenged intra-conjunctivally show clinical symptoms (palpable lesions) after 6-9 weeks. Nine weeks after showing clinical symptoms some (26.67%) possums still seemed to be in ‘good health’, and the necropsy data also showed that those possums were not severely infected and could have lived for several more weeks. This means that intra-conjunctival challenged possums can survive between 16-20 weeks post-challenge, and some individuals possibly even much longer (Corner 2003). In the wild the duration of the pre-clinical stage remains unclear, but the survival time of possums after clinical infection occurs is estimated to be 4-7 months (Ramsey, 2003). Unfortunately not all animals get infected after intra-conjunctival challenge (Corner, 2003), which is a major disadvantage.
A reliable challenge method that would cause a slower disease progression than the currently used intra-tracheal challenge would be preferable, because that way the activated immune system of the vaccinated possum would have more time to react to invading organisms and have a better opportunity of preventing the spread of infection in the body. A slower disease progression would also help to differentiate between different phases of the disease (pre-clinical, clinical, generalised and terminal infection), which could make the protective capacities of different vaccines more clear. With the current aerosol challenge the different vaccines are mainly being compared among possums that suffer from the generalised and terminal phase of the disease.

Although it would be ideal to test more vaccines against disease caused by natural transmission, Corner showed that this method is unreliable and unpractical for to use in vaccination efficacy trials with captive possums. Of all the captive possums housed together with infected individuals only a few possums got ‘naturally’ infected (Corner, 2002). A new challenge method that has the potential to generate disease in possums similar to disease in wild possums after natural Tb infection is currently being developed. The new challenge method involves subcutaneous injection of less than 50 CFU in one of the front paws, in the skin flap of the two outer most fingers (N.T.E. Holtslag, 2010).

Scoring system: Liver
In the liver several granuloma characteristics were used to differentiate between the severity of infection among the treatment groups. None of the characteristics turned out to be able to show significant differences among the treatment groups. However both the Tno granulomas and the actual granuloma size were correlated with a lot of relevant measurements. The Tno granulomas correlated significantly with the lung AFO score and the bacterial counts of lung and spleen. And the actual granuloma size and stage correlated with each other; the actual size correlated with the size index as well as the bacterial counts of the spleen. 
This indicates that both characteristics could prove to be interesting measurements that could be used to estimate the extent of Tb in possums following experimental challenge, for example as occurs in vaccine trials. However, bigger sample sizes would most likely be needed to provide significant results among different treatment groups.

Scoring system: Spleen
Scoring granuloma characteristics in the spleen does not seem to be a reliable method to differentiate between different treatment groups, at least not when sample sizes are low. The mean size and stage score of the spleen lesions varied quite a lot among the treatment groups and only the spleen granuloma stage correlated significantly with the stages in the liver, indicating a very slim correlation between other measurements that were used in this study. Whether or not spleen granuloma characteristics are useful to differentiate between tuberculosis infection in large groups of animals remains to be seen. 

Scoring system: Lung
The microscopic examination of granuloma characteristics in the lung was limited, because the estimation of the size and stage of different granulomas was not possible in heavily affected and consolidated parts of the lungs. Therefore we decided only to measure the size and estimate the stage of tuberculous lesions in apparently healthy lung tissue in our scoring system. As a result of this limitation our scoring system is not suitable to score tuberculous granulomas in the lung, as was also shown by the statistical analysis. For example, the lungs of the control animals were so severely affected that there was no healthy tissue left on the histological sample, which made us score all the lung samples with ‘No visible granulomas present in healthy lung tissue’.

The extent of the consolidation was not measured on the histological slides, because some samples were bigger than others, and it is generally accepted that the percentage of lung weight compared to body weight is a valid indicator of the extend of consolidation present (Collins, 2007). On the other hand, scoring the amount of AFOs present in the lung proved to be a good method to determine the severity of infection present in the lung. The AFO score was significantly different among the treatment groups and it correlated with both lung and spleen bacterial counts as well as the Tno granuloma present in the liver. 

Scoring system in general
In this study the lung, liver and spleen were used to assess the appearance of a generalised disease in the possums after aerosol challenge with M. bovis. 
Sensitivity of histological examination of only 3 organs is not extremely high, especially not for relatively big organs like the lung and liver, because a histological slide contains only a very small percentage of the whole organ. Although lesions in the liver are often very randomly distributed throughout the parenchyma (Cooke, 1995). 
Including multiple organs in the examination would increase the chance of finding tuberculous lesions and thus increase sensitivity of the scoring system (less false negative results). On the other hand the specificity might decrease by including more tissue slides in the examination (more false positive results), because you would have a greater chance of finding potentially tuberculous lesions caused by other factors. Possible differential diagnoses for histological confirmed tuberculous lesions in the liver, lung or kidney include either lipid, a parasite, mineral, foreign body, adiaspiromycosis, interstitial nephritis, nephrosis or no significant finding (Cooke, 1995).
As described in the introduction, evidence of Tb infection in possums is often found in the kidneys, adrenal glands and bone marrow, in addition to being in the liver and spleen, due to haematological spread of infection (Jackson, 1995a-b; Cooke, 1995-1999). Since these organs are all considered to be indicative of a generalised infection, including them in the microbiological and microscopic examination of this study could have given a better overview of the extent of disease in the animals.
In particular, a bacterial count of a liver sample would have been a useful addition, because all animals in the trail here had lesions in their liver. Comparing the bacterial count of the liver with both the Total number of granulomas and the size and stage of the scored granulomas would have been interesting.
In contrast to the organs, microbiological and microscopic examination of the superficial and deep axillary lymph nodes and inguinal lymph centres does not seem to be very relevant. These lymph nodes seldom show lesions in either macroscopic or microscopic examination of intra-tracheally challenged possums (Corner, 1980-1981; Buddle, 1994). But with both intra-tracheal and intra-conjunctival challenges microscopic lesions in these lymph nodes can be found (Corner, 2003). Infection in these lymph nodes could easily have developed through haematogenous or haematogenous and lymphatic routes (Cooke 1995).
It would also be interesting to know whether the mesenteric lymph centres were infected in these intra-tracheal challenged possums, because that would give more evidence to the assumed hypothesis that the infection of the oral tract in most cases is caused by ingestion of infectious mucus originating from the respiratory tract (Jackson, 1995b). Because these possums did not show fistula, there would have been no interference with the other hypothesis that the oral tract could get infected by ingestion of infectious fluid from fistula of infected lymph nodes during the grooming process. Proving that the main route of infection in the oral tract is by ingestion of fluids from the respiratory tract would be interesting because of other possible ways of Tb transmission between possums.

Conclusion
Some of the new attenuated mycobacterial vaccines tested in this trail seemed to be significantly better at protecting possums against experimental infection with M. bovis. And if oral vaccination with BCG can already give a 95-96% efficacy of protecting free-ranging possums against Tb infection (Tompkins, 2009), then potentially oral vaccination with strain two and maybe even strain one or five would give an even better level of protection. Since over 90% of wild populations can be reached with the use of aerial bait drop and bait-stations, such vaccination would certainly provide wild possum populations with enough immunity against natural M. bovis infection to prevent Tb transmission between wild animals, and between wildlife and livestock.
However further studies will have to determine whether or not any of these new attenuated strains will be suitable to replace BCG in large scale vaccine programs in wild possum populations. Although the results so far look very promising, the repeatability of the protection generated by the different strains will have to be further evaluated, most likely with larger numbers of animals per treatment group. 
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Appendix I: Table  1. Possum Vaccine Trail: vaccinated at 27th of May 2009







































Strain 5(n= 6)	1 x 106 cfu in 0.5 mlSub/cut	9989	55	F	1.65	1.75
		9910	73	F	2.50	2.7
		9955	56	M	2.50	2.65
		9957	64	M	2.70	2.7
		9921	74	F	2.75	2.75
		9966	71	M	3.70	3.75
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